Sanofi
Search results
Genzyme was an American biotechnology company that produced enzyme replacement therapies for rare genetic diseases. It was acquired by Sanofi in 2011 and integrated into its brand in 2022.
Feb 3, 2022 · Eleven years after Sanofi bought Genzyme for about $20.1 billion, the parent company said Thursday it will no longer call its specialty care unit Sanofi Genzyme ― just Sanofi, as part of a ...
Aug 6, 2015 · Nexviazyme is a new enzyme replacement therapy that targets the M6P receptor to clear glycogen build-up in muscle cells and improve respiratory function and walking distance in late-onset Pompe disease patients. The FDA approval is based on positive Phase 3 data and Nexviazyme is expected to be available in the U.S. in the coming weeks.
Feb 16, 2011 · Sanofi-Aventis has ended a nine-month pursuit of US biotech company Genzyme with a $20.1bn deal worth $74 a share, Bloomberg says. The French drugmaker will now be able to add rare disease ...
- Joseph Cotterill
Feb 16, 2011 · Sanofi-Aventis brought an end to its protracted pursuit of Genzyme with an agreed $20.1bn cash takeover of the US biotech company, coupled with additional conditional payments over the next...
- Cardiff Garcia
Feb 16, 2011 · Sanofi-aventis announced a $20.1 billion deal to buy Genzyme, a biotech company focused on rare diseases and multiple sclerosis. The acquisition was expected to be accretive and create a new growth platform for sanofi-aventis.
Feb 16, 2011 · French pharmaceuticals major Sanofi-Aventis SA confirmed Wednesday it has struck a deal to buy U.S. peer Genzyme Corp. for a total of $20.1 billion in cash, along with a series of milestone...
